Core Viewpoint - Shenzhen MicuRx Pharmaceuticals, Inc. reported a significant revenue growth of 40.12% year-on-year for the first three quarters of 2025, driven by increased sales of its products, particularly Sidaracizumab and Siglec-1 [1] Financial Performance - The company achieved a total revenue of 674 million yuan in the first three quarters [1] - Sales revenue for Sidaracizumab increased by 18.76% year-on-year [1] - Sales revenue for Siglec-1 surged by 136.13% year-on-year [1] Product Development and Strategy - MicuRx Pharmaceuticals has developed a global strategy based on early research in China, leveraging a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that combines AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - As of June 30, the company has two innovative drugs with multiple indications globally marketed, focusing on five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]

Core Points - The Shanghai Composite Index closed at 3961.62 points, above the six-month moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 259 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3961.62 points, indicating a slight decline of 0.63% [1] - The total trading volume for A-shares today is reported at 157.91 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 259 A-shares have broken through the six-month moving average, with the highest deviation rates observed in stocks such as: - Yatong Precision Engineering (8.20%) - Excellent New Energy (7.57%) - Deyuan Pharmaceutical (7.38%) [1] - Other stocks with smaller deviation rates include: - New Hope - Shanghai Phoenix - Angli Education, which have just crossed the six-month line [1] Notable Stocks and Their Metrics - Top stocks with significant price changes and their metrics include: - Yatong Precision Engineering: +9.76%, turnover rate 31.45%, six-month line 23.27 yuan, latest price 25.18 yuan, deviation rate 8.20% [1] - Excellent New Energy: +9.90%, turnover rate 2.44%, six-month line 45.62 yuan, latest price 49.07 yuan, deviation rate 7.57% [1] - Deyuan Pharmaceutical: +11.83%, turnover rate 8.02%, six-month line 38.03 yuan, latest price 40.84 yuan, deviation rate 7.38% [1]

Core Insights - Shenzhen MicuRx Biotech Co., Ltd. reported a significant revenue growth of 40.12% year-on-year, reaching 674 million yuan in the first three quarters of 2025, with Q3 revenue at 268 million yuan, marking a 49.51% increase [1] - The net profit attributable to shareholders for Q3 was 41.1753 million yuan, while the net profit for the first three quarters was 70.7675 million yuan [1] - The growth in performance is primarily driven by increased sales of the products Sidabenan and Siglecatin, with Sidabenan sales up 18.76% and Siglecatin sales soaring by 136.13% year-on-year [1] Company Strategy - MicuRx is leveraging a global development strategy based on early research in China, assembling a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that utilizes AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - MicuRx has successfully developed first-in-class and best-in-class innovative drugs, with two innovative drugs already marketed globally across multiple indications [1] Product Portfolio - The company has established a diverse pipeline of research projects with differentiated advantages and global competitiveness in five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]

Core Points - The Shanghai Composite Index is at 3966.25 points, above the six-month moving average, with a decline of 0.52% [1] - A total of 257 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The total trading volume of A-shares today is 115.87 billion yuan [1] - Stocks with the highest deviation rates include: - Yatong Precision Engineering: 8.41% deviation, closing at 25.23 yuan, with a daily increase of 9.98% and a turnover rate of 27.37% [1] - Aorui Technology: 6.91% deviation, closing at 3.56 yuan, with a daily increase of 9.88% and a turnover rate of 8.56% [1] - Zhuoyue New Energy: 6.42% deviation, closing at 48.54 yuan, with a daily increase of 8.71% and a turnover rate of 1.83% [1] Additional Notable Stocks - Other stocks with significant performance include: - Hualan Group: 5.49% deviation, closing at 17.75 yuan, with a daily increase of 7.58% [1] - Wento Holdings: 5.09% deviation, closing at 2.59 yuan, with a daily increase of 5.71% [1] - Stocks with smaller deviation rates that just crossed the six-month line include Southeast Electronics, Meixin Yishen, and Renfu Pharmaceutical [1]

Group 1 - Microchip Biotech (688321.SH) reported its Q3 2025 results, with 25 institutional investors holding a total of 137 million shares, representing 33.51% of the company's total equity as of October 30, 2025 [1] - The top ten institutional investors collectively hold 32.82% of the shares, a decrease of 3.37 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four funds increased their holdings, accounting for a 0.42% increase, while one fund, Huatai Baoxing KERONG A, saw a slight decrease [2] - Eleven new public funds disclosed their holdings this period, including Penghua CSI 1000 Index Enhanced A and Huaxia Zhisheng New Star Stock A [2] - One foreign fund, Vertex Technology Fund (III) Ltd, reduced its holdings by 0.82% compared to the previous quarter [2]

Core Viewpoint - The company reported a significant increase in revenue for the first nine months of 2025, driven primarily by the sales of its products, with notable growth in specific product lines [3]. Financial Performance - The company's revenue for the period from January to September 2025 grew by 40.12%, attributed to increased sales of its products, particularly: - Sales revenue from Sidabamine increased by 18.76% - Sales revenue from Siglecatin surged by 136.13% [3]. Audit Status - The financial statements for the third quarter were not audited [3][6]. Shareholder Information - There were no changes reported in the top ten shareholders or any significant movements in shareholding due to stock lending activities [5][6]. Other Important Information - The company confirmed that the financial report is accurate and complete, with no significant omissions or misleading statements [2][4].

Core Viewpoint - Microchip Biotech (688321.SH) reported a significant increase in revenue and profit for Q3 2025, driven by strong sales of its innovative drugs, particularly Sidabone and Siglitazone [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 674 million yuan, representing a year-on-year growth of 40.12% [1] - In Q3 2025, the company generated a revenue of 268 million yuan, showing a year-on-year increase of 50% and a quarter-on-quarter growth of 10% [1] - The quarterly profit expanded to 41.18 million yuan, with total profit for the first three quarters reaching 70.77 million yuan [1] Product Performance - The growth in revenue is primarily attributed to the sales of Sidabone, which saw a year-on-year revenue increase of 18.76%, and Siglitazone, which experienced a remarkable year-on-year revenue growth of 136.13% [1] - Microchip Biotech has successfully launched two first-in-class innovative drugs, Sidabone (Aipusha®) and Siglitazone (Shuangluoping®), in multiple markets including mainland China, Japan, and Taiwan [1] Industry Recognition - The company has been recognized as a leading biotech firm at the 2025 China Pharmaceutical Decision-Makers Summit and received an award for Siglitazone as an industry-leading innovative drug [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Microchip Biotech, reporting a significant revenue increase and net profit for the third quarter of 2025 [1] Group 2 - Microchip Biotech's revenue for the first three quarters of 2025 is approximately 674 million yuan, representing a year-on-year increase of 40.12% [1] - The net profit attributable to shareholders of the listed company is about 70.77 million yuan [1] - The basic earnings per share stand at 0.1735 yuan [1] - As of the report, Microchip Biotech has a market capitalization of 11.6 billion yuan [1]

深圳微芯生物科技股份有限公司 2025 年第三季度报告 深圳微芯生物科技股份有限公司 2025 年第三季度报告 证券代码：688321 证券简称：微芯生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 267,559,191.39 | 49. ...

Core Insights - Microchip Biotech reported a third-quarter revenue of 268 million yuan, representing a year-on-year growth of 49.51% [1] - The net profit for the third quarter was 41.1753 million yuan [1] - For the first three quarters, the total revenue reached 674 million yuan, showing a year-on-year increase of 40.12% [1] - The net profit for the first three quarters amounted to 70.7675 million yuan [1]